Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
LEXINGTON, Mass., Jan. 26, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2015 fourth quarter and year-end financial results after the market closes on Tuesday, February 16, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, February 16, 2016, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-4018 (U.S.) or 1-201-689-8471 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call in the Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.
Media Contact: Susan Heins, Pure Communications [email protected] 864-286-9597 Investor Contact: Matt Clawson, Pure Communications [email protected] 949-370-8500
